They concluded that asymptomatic reductions in cardiac function are common in breast cancer patients treated with doxorubicin and that NT-proBNP may serve as a convenient serum biomarker for early detection of cardiotoxicity induced by anthracycline [28]. The gene discussed is NPPB; the disease is breast carcinoma.